Saliva Test Study for Endometriosis Patients Starting Dienogest
Compares saliva samples with response to dienogest in women with endometriosis.
Plain-language title generated from the registry record
Registry title: Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy
Key facts
- Where
- Udine, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT06414720, who can take part
Where in Italy
- University of UdineUdine, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Udine
- Trial code
- NCT06414720
- Record updated
- 2 April 2025
- Original description
This study aims to analyze the salivary miRNA specific for patients diagnosed with endometriosis, specifically evaluating the miRNA profile of patients who respond versus those who do not respond to progestin therapy. Ninety patients attending the Chronic Pelvic Pain Clinic will be recruited, and they will be asked to provide a saliva sample before starting medical therapy. The response to the therapy will be evaluated after 4 months from the beginning of the therapy itself.Read full original descriptionShow less
Salivary MicroRNA in Endometriosis: Correlation With Progestin Treatment Response: A Prospective Observational Study
This study aims to analyze the salivary miRNA specific for patients diagnosed with endometriosis, specifically evaluating the miRNA profile of patients who respond versus those who do not respond to progestin therapy. Ninety patients attending the Chronic Pelvic Pain Clinic will be recruited, and they will be asked to provide a saliva sample before starting medical therapy. The response to the therapy will be evaluated after 4 months from the beginning of the therapy itself.
Inclusion: Age > 18 years; Fertile age; Clinical-ultrasound diagnosis or histological diagnosis of endometriosis; Informed consent.
Exclusion: Currently undergoing progestin therapy; Chronic pelvic pain syndrome with or without central sensitization assessed with the Central Sensitization Inventory Test (CSI); Neoplasia, diabetes, BMI > 30 kg/m2, coagulopathies, autoimmune diseases, or other conditions that may affect salivary miRNA measurement; Pregnancy; Pre-menarcheal or post-menopausal status.